Chronic Lymphocytic Leukemia Clinical Trial Landscape

Active Phase 3 CLL Programs (2026)

Active Phase 2 Programs

Phase 4 / Post-Approval Studies

What Is Chronic Lymphocytic Leukemia?

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries, arising from the clonal expansion of mature B lymphocytes. The disease is characterized by accumulation of CD5+/CD19+/CD23+ B cells in the blood, bone marrow, and lymphoid organs. Unlike acute leukemias, CLL typically follows an indolent course, many patients are managed with watch-and-wait for years before treatment is needed.

CLL is divided into two molecular subtypes with dramatically different prognoses: mutated IGHV (immunoglobulin heavy chain variable region), where the leukemic clone has undergone somatic hypermutation, carries a favorable prognosis with median survival exceeding 10 years. Unmutated IGHV CLL is more aggressive, with median survival closer to 5-8 years without modern therapy. High-risk cytogenetics (del(17p), TP53 mutation, del(11q)) further stratify prognosis and guide treatment selection.

Small lymphocytic lymphoma (SLL) is the same disease as CLL but presenting with lymphadenopathy rather than peripheral blood involvement, the two share the same biology, genetics, and treatment approach.

The CLL Treatment Landscape in 2026

The Venetoclax Revolution

Venetoclax (Venclexta, AbbVie/Genentech) transformed CLL treatment by directly targeting BCL-2, the anti-apoptotic protein that CLL cells depend on for survival. The CLL14 trial established venetoclax + obinutuzumab as a 12-month fixed-duration regimen with durable remissions in treatment-naive CLL. The MURANO trial established venetoclax + rituximab in relapsed/refractory CLL. The key advantage of venetoclax-based therapy is fixed-duration treatment, patients achieve MRD (minimal residual disease) negativity and stop therapy, enjoying treatment-free remissions that indefinite BTK inhibitor therapy cannot offer.

The BTK Inhibitor Era

BTK (Bruton's tyrosine kinase) inhibitors block B-cell receptor signaling that CLL cells require for proliferation and survival. Ibrutinib (Imbruvica, AbbVie/J&J) was the first approved, demonstrating dramatic responses in both treatment-naive and relapsed CLL. Second-generation covalent BTKis, acalabrutinib (Calquence, AstraZeneca) and zanubrutinib (Brukinsa, BeOne), showed superior safety with fewer off-target kinase effects. The ALPINE trial demonstrated zanubrutinib's superiority over ibrutinib in PFS and atrial fibrillation risk, making zanubrutinib the preferred covalent BTKi in most settings.

The major limitation of covalent BTKis is resistance, particularly the C481S BTK mutation, which prevents covalent bond formation. Pirtobrutinib (Jaypirca, Eli Lilly/Loxo) is the first approved non-covalent BTKi, binding BTK reversibly and overcoming C481S resistance. Pirtobrutinib is FDA-approved in CLL after two prior lines of therapy including a BTKi.

BeOne's Portfolio Dominance

BeOne Medicines is running the most aggressive CLL trial program in 2026, with 5 Phase 3 trials across two molecules: sonrotoclax (next-generation BCL-2 inhibitor) and BGB-16673 (BTK degrader). The strategy is to establish a complete CLL portfolio that replaces venetoclax (with sonrotoclax) and covalent BTKis (with the degrader), capturing the entire treatment algorithm with BeOne molecules. If successful, this would be a historic pipeline execution.

The Emerging BTK Degrader Story

PROTAC-based BTK degraders represent the next step beyond non-covalent BTKis. Where pirtobrutinib inhibits BTK activity while leaving the protein intact, degraders eliminate the BTK protein entirely through ubiquitin-mediated proteasomal degradation. BGB-16673 (BeOne) is now in Phase 3, the first BTK degrader to reach Phase 3 in any indication. NX-2127 (Nurix) and other degraders are in earlier development. The unresolved question is whether protein elimination offers meaningful clinical advantages over non-covalent inhibition, or whether the improved pharmacology translates to better efficacy.

Key Questions Driving CLL Trials in 2026

• Fixed-duration vs. continuous therapy: Venetoclax-based fixed-duration regimens offer treatment-free remissions; BTKi continuous therapy offers manageable chronic treatment. Which approach maximizes quality-adjusted survival?
• Triplet vs. doublet combinations: Does adding a third agent (e.g., venetoclax to BTKi + anti-CD20, or obinutuzumab to venetoclax + BTKi) improve outcomes enough to justify increased toxicity and cost?
• MRD-guided treatment duration: Can undetectable MRD (measured by next-generation sequencing or flow cytometry) reliably guide treatment discontinuation, and what depth of MRD negativity is sufficient?
• Sequencing after BTKi + venetoclax: As more patients receive both BTKi and venetoclax, the post-both-mechanisms relapsed setting is emerging as a major unmet need. Pirtobrutinib, non-BTK-directed therapies, CAR-T, and clinical trials are the options.
• BTK degrader vs. non-covalent BTKi: The BGB-16673 vs. pirtobrutinib trial will provide the first direct clinical comparison, answering whether degrading BTK beats inhibiting it in the post-covalent BTKi setting.

Frequently asked questions

Related Disease Pages

• Mantle Cell Lymphoma (MCL) Clinical Trials: BTK inhibitors, degraders, CELESTIAL-RRMCL
• Follicular Lymphoma Clinical Trials: bispecific antibodies, PI3K inhibitors
• DLBCL Clinical Trials: CAR-T, bispecifics, novel combinations
• Non-Hodgkin Lymphoma Overview: all NHL subtypes
• Leukemia Clinical Trials: AML, ALL, CML, MDS